<![CDATA[FDA OKs Pembrolizumab/EV Combo in Muscle Invasive Bladder Cancer]]>

<![CDATA[Pembrolizumab Plus EV Regimens Receive FDA Approval for Muscle Invasive Bladder Cancer]]>

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in p

<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>

Antibody-Drug Conjugates in Perioperative Treatment of Muscle-Invasive Bladder Cancer: Expert Perspectives

Are your treatment plans for MIBC current? Learn about the latest guidelines for perioperative antibody-drug conjugate (ADC)-based combinati

La inmunoterapia posquirúrgica ayudó a las personas con cáncer de vejiga de riesgo alto a vivir sin cáncer por más tiempo

En un estudio del NCI, se observó que administrar pembrolizumab a los pacientes después de la cirugía para el cáncer de vejiga con invasión

<![CDATA[FDA Approves Atacicept-vymj to Reduce Proteinuria in IgA Nephropathy]]>